Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

Pons, Marion ; Georgiadis, Stylianos ; Østergaard, Mikkel ; Ahmadzay, Zohra Faizy ; Glintborg, Bente ; Heberg, Jette ; Christensen, Sara Nysom ; Rasmussen, Simon ; Loft, Anne Gitte and Castrejón, Isabel , et al. (2025) In Joint Bone Spine 92(3).
Abstract

Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Patients and methods: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons... (More)

Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Patients and methods: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. Results: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. Conclusion: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bDMARD, Epidemiology, Spondyloarthritis
in
Joint Bone Spine
volume
92
issue
3
article number
105824
publisher
Elsevier Masson SAS
external identifiers
  • pmid:39608666
  • scopus:85215619493
ISSN
1297-319X
DOI
10.1016/j.jbspin.2024.105824
language
English
LU publication?
yes
id
d06591ab-d394-45c5-a9c9-a144cdb1ed13
date added to LUP
2025-03-21 11:09:33
date last changed
2025-07-11 20:02:20
@article{d06591ab-d394-45c5-a9c9-a144cdb1ed13,
  abstract     = {{<p>Objectives: In axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating secukinumab, we aimed to assess retention rates and proportions of patients achieving remission and low disease activity (LDA), according to disease activity measures and patient-reported outcomes at 24 and 48 months. Patients and methods: Data on patients with axSpA and PsA who initiated secukinumab treatment were pooled from 13 European registries. Analyses were performed overall and stratified according to the number of previous biologic/targeted synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs, 0/1/≥ 2). Kaplan-Meier plots and Cox regression analyses were performed to assess and compare secukinumab retention rates. Comparisons of remission and LDA rates were performed by logistic regression analyses. Results: The overall 24-/48-month secukinumab retention rates were 61%/51% in 767 axSpA patients, and 64%/49% in 975 PsA patients, respectively. Compared to b/tsDMARD naïve patients, a higher risk of withdrawal from secukinumab was found for those with ≥ 2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA. Generally, remission and LDA rates were numerically higher in b/tsDMARD naïve patients. After adjustment for confounders, statistically significantly higher remission and LDA rates were found for b/tsDMARD naïve patients compared to patients with ≥ 2 prior b/tsDMARDs at 24 months in axSpA and PsA. Conclusion: This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.</p>}},
  author       = {{Pons, Marion and Georgiadis, Stylianos and Østergaard, Mikkel and Ahmadzay, Zohra Faizy and Glintborg, Bente and Heberg, Jette and Christensen, Sara Nysom and Rasmussen, Simon and Loft, Anne Gitte and Castrejón, Isabel and Sánchez-Alonso, Fernando and Iannone, Florenzo and Nordström, Dan and Hokkanen, Anna Mari and Ciurea, Adrian and Nissen, Michael J. and Závada, Jakub and Pavelka, Karel and Rotar, Ziga and Pirkmajer, Katja Perdan and Michelsen, Brigitte and Mielnik, Pawel and Bernardes, Miguel and Khmelinskii, Nikita and Laas, Karin and Vorobjov, Sigrid and Codreanu, Catalin and Macfarlane, Gary J. and Jones, Gareth T. and Gudbjornsson, Bjorn and Palsson, Olafur and Wallman, Johan K. and van der Horst-Bruinsma, Irene and Onen, Fatos and Hetland, Merete Lund and Ørnbjerg, Lykke Midtbøll}},
  issn         = {{1297-319X}},
  keywords     = {{bDMARD; Epidemiology; Spondyloarthritis}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Elsevier Masson SAS}},
  series       = {{Joint Bone Spine}},
  title        = {{Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis}},
  url          = {{http://dx.doi.org/10.1016/j.jbspin.2024.105824}},
  doi          = {{10.1016/j.jbspin.2024.105824}},
  volume       = {{92}},
  year         = {{2025}},
}